Posted by Michael Wonder on 04 Jul 2021
Solasia announces submission of new drug application for anti-cancer drug darinaparsin for peripheral T-cell lymphoma in Japan
30 June 2021 - New drug application filed in Japan ahead of anywhere else in the world.
Solasia Pharma today announced submission of a new drug application for its new anti-cancer drug darinaparsin (generic name, development code: SP-02) as a treatment for relapsed or refractory peripheral T-cell lymphoma to the Ministry of Health, Labour and Welfare.
